FG-T903

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameFG-T903
Drug Alias Nametriple PVRIG check point inhibitor/PD-L1 check point inhibitor/TIGIT check point inhibitor (FutureGen Biopharm)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionProgrammed cell death protein 1 modulatorsT cell immunoglobulin and ITIM domains modulatorsT lymphocytes stimulants +[5] 
TargetsT cell immunoglobulin and ITIM domainsProgrammed cell death protein 1Transmembrane protein PVRIG
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesFutureGen Biopharm (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFutureGen Biopharm (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A